// App-Quantinova.ai

520 : Evaluation of biomarker association with efficacy for abiraterone acetate (AA) plus prednisone (P) with or without exemestane (E) in postmenopausal patients (pts) with estrogen receptor-positive (ER+) metastatic breast cancer (mBCa) progressing after a nonsteroidal aromatase inhibitor (NSAI).

Researchers

Presenter

  • Weimin Li

Principal Investigators

  • Deborah Sokol Ricci

  • Mario Campone

  • Igor Bondarenko

  • Irina Zbarskaya

  • Etienne Brain

  • Marina B. Stenina

  • Olga Ivanova

  • Marie-Pascale Graas

  • Patrick Neven

  • Thian San Kheoh

  • Margaret K. Yu

  • Michael Gormley

  • Jason L. Martin

  • Michael Schaffer

  • Kathy Zelinsky

  • Daniel F. Hayes

  • Stephen R. D. Johnston

  • Thomas W. Griffin

Medical Centers

  • NN Petrov Research Institute of Oncology, St Petersburg, Russia

  • N. N. Blokhin Russian Cancer Research Center, Moscow, Russia

  • Janssen Research and Development, LLC, Spring House, PA

  • State Medical Academy, Municipal Clinical Hospital #4, Dnepropetrovsk, Ukraine

  • University of Michigan Comprehensive Cancer Center, Ann Arbor, MI

  • Janssen Research and Development, High Wycombe, United KingdomThe Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, London, United KingdomCHC, Liege, Belgium

  • Janssen Research & Development, LLC, Raritan, NJ

  • Janssen Research & Development, Los Angeles, CA

  • Leningrad Regional Oncology Dispensary, Saint Petersburg, Russia

  • Texas Oncology - Baylor Charles A. Sammons Cancer Center and The US Oncology Network, Dallas, TX

  • Institut de Cancerologie de l'Ouest Paul Papin, Angers, France

  • Hopital Rene Huguenin, Saint-Cloud, France

Locations

  • United States

  • Ukraine

  • France

  • Russia

  • Belgium

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

Biomarkers

  • Aromatase

  • Circulating tumor cells

  • Cytochrome P450 Family 17 subfamily A member 1

Drug/Treatment

  • CB-7598

  • Exemestane

  • Prednisone

  • Androgen Tear

Outcome

  • Positive

Study Design

  • N/A

Phase

  • NA

Study Id's

  • NCT01381874

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved